|
1. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 91(Suppl):S72-S75;1991. 2. Gilardi, GL. Pseudomonas and related genera. In Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, DC, 429-441;1991. 3. Costerton JW. Pseudomonas aeruginosa in nature and disease. In Sabath LD, ed. Pseudomonas aeruginosa the organism, disease it causes, and their treatment, 15-24;1980. 4. Finland M. Changing patterns of susceptibility of common bacteriological pathogens to antimicribial agents. Ann Inter Med 76:1009-1036;1972. 5. Olsen B, Weinstein RA, Nathan C, Chamberlin W, Cabins SA. Epidemiology of endemic Pseudomonas aeruginosa: why infection control efforts have failled. J Infect Dis 150:808-817;1984. 6. Celis RA, Gatell JM, Alnela M. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 93:318-325;1988. 7. Liu PV. The role of various fractions of Pseudomonas aeruginosain its pathogenesis: III, identity of the lethal toxins produces in vitro and in vivo. J Infect Dis 116:481;1966. 8. Liu PV. Extracellular toxins of Pseudomonas aeruginosa. J Infect Dis 130(Suppl):S94-S95;1974. 9. Gray GL, Smith DH, Baldridge JS, Harkins RN, Vasil ML, Chen EY. Heyneker HL. Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 81:2645-2649;1984. 10. Iglewski BH, Kabat D. NAD+-dependent inhibition of protein synthesis by Pseudomonasaeruginosa toxin. Proc Natl Acad Sci USA 72:2284-2288;1975. 11. Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 angstrom resolution. Proc Natl Acad Sci USA 83:1320-1324;1986. 12. Hwang J, Fitzgerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48:129-136;1987. 13. Chow JT, Chen MS, Wu HCP, Hwang J. Identification of the carboxyl-terminal amino acids important for the ADP-ribosylation activity of Pseudomonas aeruginosa A. J Biol Chem 264:18818-18823;1989. 14. Jinno Y, Chaudhary VK, Kondo T, Adhya S, FitzGerald DJ, Pastan I. Mutational analysis of domain I of Pseudomonas exotoxin A. J Biol Chem 263:13203-13207;1988. 15. Jinno Y, Ogata M, Chaudhary VK, Willingham MC, Adhya S, FitzGerald DJ, Pastan I. Domain II mutants of Pseudomonas exotoxin A deficient in translation. J Biol Chem 264:15953-15959;1989. 16. FitzGerald DJ, Morris RE, Saelinger CB. Receptor-mediated internalization of Pseudomonas exotoxin A by mouse fibroblasts. Cell 21:867-873;1980. 17. Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The a2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pesudomonas exotoxin A. J Biol Chem 267:12420-12423;1992. 18. Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ. Processing of Pseudomonas exotoxin by a cellular protease results in the generating a 37,000 Da toxin fragement that is translocated to the cytosol. J Biol Chem 265:20678-20685;1990. 19. Bodey GP, Bolivar R, Fainstein V, Jadeja. L. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 5:279-313;1983. 20. Hancock REW. Intrinsic antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 18:653-656;1986. 21. Cryz SJ. Pseudomonas aeruginosa infections. In: Germanier R, ed. Bacterial vaccines, Academic Press, Inc, Orlando, Fla, 317-351;1984. 22. Nicas TI, Iglewski BH. The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Can J Microbiol 31:387-392;1985. 23. Stieritz DD and Holder IA. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis 131:688-693;1975. 24. Saelinger CB, Snell K, Hodler IA. Experimental studies on the pathogenesis of infections due to Pseudomonas aeruginosa: direct evidence for toxin production during Pseudomonas infection of burned skin tissues. J Infect Dis 136:5-15;1977. 25. Pavlovskis OR, Pollock M, Callahan LT, Iglewski BH. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect Immun 18:596-572;1977. 26. Cryz SJ, Furer E, Germanier R. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high molecular weight polysaccharide. Infect Immun 43:795-799;1984. 27. Cryz SJ, Furer E, Cross AS, Wegmann A, Germanier R, Sadoff JC. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine in humans. J Clin Invest 80:51-56;1987. 28. Finke M, Muth G, Reichhelm T, Thoma M, Duchene M, Hungerer KD Domdey, H, von Specht BU. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies. Infect Immun 59:1251-1254;1991. 29. Cryz SJ, Lang AB, Sadoff JC, Germanier R, Furer E. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect Immun 55:1547-1551;1987. 30. Cryz SJ, Sadoff JC, Furer E. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Microb Pathog 6:75-80;1987. 31. Wang L-Y, Frasch CE. Development of a Neisseria meningitis group B serotype 26 protein vaccine and evalution in a mouse model. Infect Immun 46:408-414;1984. 32. Guilg PA, Cracken GH, Frisch CF, Johnston KH, Hansen EJ. Antibody response of infants to cell-surface-exposed outer membrane proteins of Haemophilus influenza type B after systemic Haemophilus disease. Infect Immun 37:82-88;1982. 33. Mutharia LM, Hancock REW. Surface localization of Pseudomonas aeruginosa outer membrane porin protien F by using monoclonal antibodies. Infect Immun 42:1027-1033;1983. 34. Woodruff WA, Hancock REW. Pseudomonas aeruginosa outer membrane porin protien F: structural role and relationship to the Escherichia coli Omp A protein. J Bacteriol 171:3304-3309;1989. 35. Nikaido H, Hancock REW. Outer membrane permeability of Pseudomonas aeruginosa. In Sokatch JR, Ornston LN, eds. The Bacteria, Vol. 10, The Biology of Pseudomonas aeruginosa, Academiac Press Inc, Orlando, Flo, 145-193;1986. 36. Gotoh N, Wakebe H, Yoshihara E, Nakae T, Nishino T. Role of protein F in maitaining structural integrity of Pseudomonas aeruginosa outer membrane protein. J Bacteriol 171:983-990;1989. 37. Gilleland HE, Parker MG, Matthews JM, Berg RD. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect Immun 44:49-54;1984. 38. von Specht BU, Strigl G, Ehret W, Brendel W. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection. Infection 15:408-412;1987. 39. Clement WF, Campbell GD, Anderson WM, James HZ, Gilliland LB, Gilliland HE. Preservation of pulmonary function by an outer membrane protein F vaccine: a study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa. Chest 105:1545-1550;1994. 40. von Specht BU, Knapp B, Muth G, Broker M, Hungerer KD, Diehl KD, Massarrat K, Seemann A, Domdey H. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect Immun 63:1855-1862;1995. 41. Liau CW, Hseu TH, Hwang J. A target-specfic chimeric toxin composed of epidermal growth factor and Pseudomonas exotoxin A with a deletion in its toxin-binding domain. Appl Microbiol Biotech 43:498-507;1995. 42. Holloway BM, Krishnapillai V, Morgan AF. Chromosomal genetics of Pseudomonas aeruginosa. Microbiol Rev 43:73-1002;1979. 43. Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned gene. J Mol Biol 189:113-130;1986. 44. Shiah H-S, Chen T-Y, Chang C-M, Chow JT, Kung H-J, Hwang J. Pseudomomas exotoxin A-epidermal growth factor (EGF) mutant chimeric protein as an indicator for identifying amino acid residues important in EGF-recptor interaction. J Biol Chem 267:24034-24040;1992. 45. Voller A, Bidwell DE, Bartlett A. The enzyme linked immunosorbent assay (ELISA), Dynatech Lab, Alexzndria, Va;1979. 46. Duchene M, Barron C, Schweizer A, von Specht BU, Domdey H. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli. J Bacteriol 171:4130-4137;1989. 47. Duchene M, Schweizer A, Lottspeich F, Krauss G, Marget M, Vogel K, von Specht BU, Domdey H. Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene. J Bacteriol 170:155-162;1988. 48. Gilleland HE, Gilleland LL, Hughes EE, Matthews JM. Recombinant outer membrane protein F of Pseudomonas aeruginosa elicits antibodies that mediate opsonophagocytic killing, but not complement-mediated bacteriolysis, of various strains of P. aeruginosa. Current Microbiol 24:1-7;1992. 49. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 27:493-497;1938. 50. Holder IA. The pathogenesis of infections owing to Pseudomonas aeruginosa using the burned mouse model: experimental studies from the Shriners Burns Institute, Cincimnnati. Can J Microbiol 31:393-402;1985. 51. Cross AS, Sadoff JC, Iglewski BH, Sokol PA. Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in human. J Infect Dis 142:538-546;1980. 52. Pollack M. The role of exotoxin A in Pseudomonas disease and immunity. Rev Infect Dis 5(Suppl):S979-S984;1983. 53. Chaughary VK, Jinno Y, FitzGerald D, Pastan I. Pseudomonas exotoxin contains a specfic sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA 87:308-312;1990. 54. Pier GB, Sidberry HF, Sadoff JC. Protective immunity induced in mice by immunization with high molecular-weight polysaccharide from Pseudomonas aeruginosa. J Clin Invest 69:303-308;1978. 55. Seid RC, Sadoff JC. Preparation and characterization of detoxified lipopolysaccharide-protein conjugates. J Biol Chem 256:7305-7310;1981. 56. Homma JY, Abe C, Tanamoto K, Hirao Y, Morihara K, Tsuzuki H, Yanagawa R, Honda E, Aoi Y, Fujimoto Y, Goryo M, Imazeki N, Noda H, Goda A, Takeuchi S, Ishihara T. Effectiveness of immunization with single and multicomponent vaccines prepared from a common antigen (OEP), protease and elastase toxoids of Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink due to P. aeruginosa. Jap J Exp Med 48:183-186;1978. 57. Yamamoto M, Kubota Y, Matsuura M, Homma JY. Antibody titers in the serum of patients vaccinated with the multicomponent vaccine consisting of toxoids of protease, elastase and exotoxin and a common antigen (OEP). Jap Ass Infect Dis 60:1178-1183;1986. 58. Abe C, Shionoya H, Hirao Y, Okada K, Homma JY. Common protective antigen (OEP) of Pseudomonas aeruginosa. Jap J Exp Med 45:355-359;1975. 59. Hughes EE, Gilleland LB, Gilleland HE. Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa. Infect Immun 60:3497-3503;1992. 60. Rawling EG, Martin NL, Hancock REW. Epitope mapping of the Pseudomonas aeruginosa major outer membrane porin protein OprF. Infect Immun 63:38-42;1995. 61. Friedmann T. Gene therapy- a new kind of medicine. Trends in Biotech 11: 156-159;1993. 62. Mitani K, Caskey CT. Delivering therapeutic genes- matching approach and application. Trends in Biotech 11: 162-166;1993. 63. Chowdhury NR, Wu CH, Wu GY, Yerneni PC, Bommineni VR, Chowdhury JNR. Fate of DNA Targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. J Bio Chem 268:11265-11271;1993. 64. Eidels L, Proia RL, Hart DJ. Membrane receptors for bacterial toxin. Microbiol Rev 47:596-620;1983. 65. Kao GY, Chang L-J, Allen TM. Use of targeted cationic liposomes in enhanced DNA delivery to cancer cells. Cancer Gene Therapy 3:250-256;1996. 66. Kabanov AV, Kabanov VA. DNA complexes with polycations for the delivery of genetic material into cells. Bioconjugate Chem 6:7-20;1995. 67. Wagner E, Zatloukal K, Cotton M, Kirlappos H, Mechtler K, Curiel DT, Birnstiel ML. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 89:6099-6103;1992. 68. Ferry N, Heard JM. Liver-directed gene transfer vectors. Human Gene Therapy 9:1975-1981;1998. 69. Strauss M. Liver-directed gene therapy: prospects and problems. Gene Therapy 1:156-164;1994. 70. Huxley C. Mammalian artificial chromosomes: a new tool for gene therapy. Gene Therapy 1:7-12;1994.
|